GLP-1 agonists were approved by the FDA for weight loss in late 2014. It's a newer class of drugs better known for its ability to improve blood sugar control. These medications were actually designed to treat type II diabetes, but some have also been FDA approved to treat weight loss. The GLP-1 agonists we work with are called Semaglutide & Tirzepatide. Semaglutide is also known Ozempic or Wegovy. Tirzepatide is known as Mounjaro.
Tirzepatide is dosed at 5-15mg per week
Semaglutide is dosed at 0.5-2.4mg per week
BENEFITS OF GLP-1 AGONISTS
- Helps slow food leaving your stomach
- Helps prevent your liver from making too much sugar
- Helps the pancreas produce more insul when your blood sugar levels are high
- Can help control blood glucose
- Can reduce hyperglycemia, especially after meals
- Can reduce fasting insul and fasting glucose
- Can reduce hemoglobin A1c
- Can decrease appetite and caloric intake, while inhibiting weight gain
- Has been shown to lower triglyceride levels and oxidative stress from high LDL
- Has been shown to help induce weight loss in obese patients with higher dosing
- Helps decrease leptin and increase leptin sensitivity
- Can increase the conversion of white fat to brown fat